The role of adoptively transferred CD8 T cells and host cells in the control of the growth of the EG7 thymoma: Factors that determine the relative effectiveness and homing properties of Tc1 and Tc2 effectors

Journal of Immunology

Volumn 166, Issue 11, 2001, Pages 6500-6508

  Helmich, Brian K ^a   Dutton, Richard W ^a  

^a TRUDEAU INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 4; INTERLEUKIN 5; PERFORIN;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CARCINOGENESIS; CONTROLLED STUDY; EFFECTOR CELL; HOST CELL; IMMUNE RESPONSE; LYMPH NODE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN; T LYMPHOCYTE SUBPOPULATION; THYMOMA;

EID: 0035337444     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.166.11.6500     Document Type: Article

References (29)

1. Allison, J. P. 2000. Cancer: editorial overview. Curr. Opin. Immunol. 12:569.
2. Shresta, S., C. T. N. Pham, D. A. Thomas, T. A. Graubert, and T. J. Ley. 1998. How do cytotoxic lymphocytes kill their targets. Curr. Opin. Immunol. 10:581.
3. Rossi, D., and A. Zlotnik. 2000. The biology of chemokines and their receptors. Annu. Rev. Immunol. 18: 217.
4. Schreiber, H. 1999. Tumor immunology. In Fundamental Immunology, 4th Ed. Paul, W. E., ed. Lippincott-Raven, Philadelphia, pp. 1237-1270.
5. Yee, C., S. R. Riddell, and P. D. Greenberg. 1997. Prospects for adoptive T cell therapy. Curr. Opin. Immunol. 9:702.
6. Overwijk, W. W., A. Tsung, K. R. Irvine, M. R. Parkhurst, T. J. Goletz, K. Tsung, M. W. Carroll, C. Liu, B. Moss, S. A. Rosenberg, and N. P. Restifo. 1998. gp100/ pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J. Exp. Med. 188:277.
7. + T cells: efficacy is limited by migration away from the site and induction of nonresponsiveness. J. Immunol. 162:2858.
8. Dobrzanski, M. J., J. Reome, and R. W. Dutton. 1999. Therapeutic effects of tumor-reactive Tc1 and Tc2 CD8 T cell subpopulations in established pulmonary metastases J. Immunol. 162:6671.
9. + effector T cell subpopulations promote long term tumor immunity and protection to progressively growing tumor. J. Immunol. 164:916.
10. Dobrzanski, M. J., J. B. Reome, and R. W. Dutton. 2001. Immunopotentiating role of IFN-γ in early and late stages of type 1 CD8 effector cell-mediated tumor rejection. Clin. Immunol. 98:70.
11. Hanson, H. L., D. L. Donermeyer, H. Ikeda, J. M. White, V. Shankaran, L. J. Old, H. Shiku, R. D. Schreiber, and P. M. Allen. 2000. Eradication of established tumors by CD8 T cell adoptive immunotherapy. Immunity 13:265.
12. Granziero, L., S Krajewski, P. Farness, L. Yuan, M. K. Courtney, M. R. Jackson, P. A. Peterson, and A. Vitiello. 1999. Adoptive immunotherapy prevents prostate cancer in a transgenic animal model. Eur. J. Immunol. 29:1127.
13. Vierboom, M. P., H. W. Nijman, R. Offringa, E. I. van-der-Voort, T. van-Hall, L. van-den-Broek, G. J. Fleuren, P. Kenemans, W. M. Kast, and C. J. Melief. 1997. Tumor eradication by wild-type p53-specitic cytotoxic T lymphocytes. J. Exp. Med. 186:695.
14. Hu, J., W. Kindsvogel, S. Busby, M. C. Bailey, Y. Y. Shi, and P. D. Greenberg. 1993. An evaluation of the potential to use tumor-associated antigens as targets for antitumor T cell therapy using transgenic mice expressing a retroviral tumor antigen in normal lymphoid tissues. J. Exp. Med. 177:1681.
15. Winn, H. J. 1961. Immune mechanism in homotransplantation. II. Quantitative assay of the immunologic activity of lymphoid cells stimulated by tumor homografts. J. Immunol. 86:228.
16. Hogquist, K. A., S. C. Jameson, W. R. Heath, J. L. Howard, M. J. Bevan, and F. R. Carbone. 1994. T cell receptor antagonist peptides induce positive selection. Cell 76:17.
17. Moore, M. W., F. R. Carbone, and M. J. Bevan. 1988. Introduction of soluble protein into the class I pathway of antigen processing and presentation. Cell 54:777.
18. Rotzschke, O., K. Falk, S. Stevanovic, G. Jung, P. Walden, and H. G. Rammensee. 1991. Exact prediction of a natural T cell epitope. Eur. J. Immunol. 21:2891.
19. Shastri, N., and F Gonzalez. 1993. Endogenous generation and presentation of the ovalbumin peptide/Kb complex to T cells. J. Immunol. 150:2724.
20. Carter, L. L., and R. W. Dutton. 1995. Relative perform- and Fas-mediated lysis in T1 and T2 CD8 effector populations. J. Immunol. 155:1028.
21. Cerwenka, A., T. M. Morgan, A. G. Harmsen, and R. W. Dutton. 1999. Migration kinetics and final destination of type 1 and type 21 CD8 effector cells predict protection against pulmonary virus infection. J. Exp. Med. 189:423.
22. Cerwenka, A., T. Morgan, and R. W. Dutton. 1999. Naive, effector and memory CD8 T cells in protection against pulmonary influenza virus infection: homing properties rather than initial frequencies are crucial. J. Immunol. 163:5535.
23. Kagi, D., B. Ledermann, K. Burki, P. Seiler, B. Odermatt, K. J. Olsen, E. R. Podack, R. M. Zinkernagel, and H. Hengartner. 1994. Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice. Nature 369:31.
24. Rosen, D., J. H. Li, S. Keidar, I. Markon, R. Orda, and G. Berke. 2000. Tumor immunity in perforin-deficient mice: a role for CD95 (Fas/APO-1) J. Immunol. 164:3229.
25. Prevost-Blondel, A., E. Roth, F. M. Rosenthal, and H. Pircher. 2000. Crucial role of TNF-α in CD8 T cell-mediated elimination of 3LL-A9 Lewis lung carcinoma cells in vivo. J. Immunol. 164: 3645-51.
26. Boehm, U., T. Klamp, M. Groot, and J. C. Howard. 1997. Cellular responses to interferon-γ. Annu. Rev. Immunol. 15:749.
27. Krasagakis, K., C. Garbe, C. C. Zouboulis, and C. E. Orfanos. 1995. Growth control of melanoma cells and melanocytes by cytokines. Recent Results Cancer Res. 139:169.
28. + T cells and IFN-γ in establishing and maintaining the tumor-dormant state. J. Immunol. 162:2842.
29. Lee, J. K., T. J. Sayers, A. D. Brooks, T. C. Back, H. A. Young, K. L. Komschlies, J. M. Wigginton, and R. H. Wiltrout. 2000. IFN-γ-dependent delay of in vivo tumor progression by Fas overexpression on murine renal cancer cells. J. Immunol. 164:231.